Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Escc

November 3, 2022 updated by: Yongtao Han

Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Esophageal Squamous Cell Carcinoma

The goal of this observational study is to to clarify the focus of lymph node dissection during esophagectomy.. The main question[s] it aims to answer is:

  • provide a basis for accurate staging and the relationship between OS and lymph node dissection

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

1727

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Sichuan Cancer Hospital and Research Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

(1) Pathologic findings proved esophageal cancer (8th AJCC/UICC stage T1b-4aN0-3M0). (2) underwent esophagecomy (two-field or three-field LN dissection). (3)The primary tumor was thoracic esophageal cancer.

Description

Inclusion Criteria:

  1. Pathologic findings proved ESCC (8th AJCC/UICC stage T1b-4aN0-3M0)
  2. Underwent esophagecomy (two-field or three-field LN dissection)
  3. The primary tumor was thoracic ESCC

Exclusion Criteria:

  1. Located outside the thoracic
  2. Patients underwent salvage or R1/R2 esophagecomy
  3. The number of resected lymph nodes (RLNs) less than 15
  4. With neoadjuvant therapy(NT) or salvage chemoradiotherapy(SCRT)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
5-year survival rate of lymph nodes metastases (%) in patients
Time Frame: 2010.1.1-2017.12.30
Surgical data were retrospectively collected
2010.1.1-2017.12.30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yongtao Han

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2022

Primary Completion (Actual)

October 1, 2022

Study Completion (Actual)

October 10, 2022

Study Registration Dates

First Submitted

October 29, 2022

First Submitted That Met QC Criteria

November 2, 2022

First Posted (Actual)

November 3, 2022

Study Record Updates

Last Update Posted (Actual)

November 4, 2022

Last Update Submitted That Met QC Criteria

November 3, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • SCCH-TS2203

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Esophageal Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe